Hennigsdorf/Berlin (Germany), 15 March, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Richard Jones as Chief Executive Officer of Adrenomed, effective today. Dr. Jones brings over 25 years of experience in leadership positions in the pharmaceutical and biotech industry with a sustained record of achievements in business, clinical development and commercialization.
“I am delighted to welcome Dr. Richard Jones as the new CEO of Adrenomed. He is a highly achieved life science specialist, who provides a unique combination of strategic, financial, development and organizational capabilities to the Company. Under his leadership, Adrenomed has a strong team in place to lead its first-in-class drug candidate Adrecizumab through late-stage clinical development towards commercialization. Our goal is to bring an urgently needed, effective precision medicine for treating sepsis to intensive care units,” said Prof. Dr. Erich Schlick, Chairman of Adrenomed’s Supervisory Board.
“On behalf of the entire Supervisory Board, I would also like to thank Dr. Wolfgang Baiker, former CEO of Adrenomed, for his contribution to the company and wish him well for the future,” he added.
Dr. Richard Jones, CEO of Adrenomed, said: “I am excited to be joining Adrenomed at a pivotal phase of the Company’s evolution. Sepsis is responsible for between one third and one half of deaths of hospitalized people. This equates to 11 million people worldwide dying each year which is higher than the top 3 cancer conditions combined and represents a significant high unmet medical need. Adrenomed’s innovative biomarker guided treatment approach, with Adrecizumab, is targeting the endothelial barrier dysfunction as a major cause of mortality in sepsis. I look forward to working with the team and advancing the late-stage clinical development of Adrecizumab to provide a new treatment option for critically ill patients.”
Richard Jones joins Adrenomed from Fusion Antibodies Plc, a contract research organization specialized in antibody engineering. As CEO of Fusion Antibodies Plc, Richard successfully implemented a new growth strategy in the global antibodies marketplace. Previously, Richard served as CEO for a number of UK and European private companies as well as SVP, Head of Europe for a US based public company. Before this he gained expertise at Novartis and GSK as VP, Medicines Commercialization Leader Global Haematology at both companies. In these roles, Richard was responsible for three regulatory submissions and initiation of several new drug development programs, plus the planning and execution of three global product launches. Richard also worked with Genzyme Corporation and as International Franchise Director for Shire Pharmaceuticals. He holds a BSc in Biochemistry and PhD in Molecular Oncology from University of Surrey.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 207780
MC Services AG
Eva Bauer / Julia von Hummel
phone: +49 (0)89 21022880